Survodutide: Dual GLP-1/Glucagon Agonist Enters Phase 3 for MASH and Obesity

Survodutide (BI 456906) is an investigational peptide developed through a collaboration between Boehringer Ingelheim and Zealand Pharma. Structurally, it is a 29-amino-acid peptide derived from the native glucagon sequence with targeted substitutions at positions 18, 20, and 23 (swapped to GLP-1 residues), position 16 (swapped to an exendin-4 residue), and modifications at positions 24 and 27–29 to optimize receptor binding and pharmacokinetics. A fatty diacid moiety conjugated to the lysine side chain at position 24 extends its plasma half-life, enabling once-weekly subcutaneous administration.

Unlike mono-agonists that target only the GLP-1 receptor, survodutide simultaneously activates both the glucagon receptor (GCGR) and the GLP-1 receptor (GLP-1R). This dual-agonist profile positions it within a new generation of metabolic peptides designed to address multiple pathophysiological axes — appetite regulation, energy expenditure, and hepatic lipid metabolism — through a single molecule.

Boehringer Ingelheim holds the exclusive global license for development and commercialization, while Zealand Pharma retains milestone and royalty rights. The compound received FDA Breakthrough Therapy designation for MASH, accelerating its regulatory pathway.

The pharmacological rationale for survodutide rests on the complementary metabolic effects of its two target receptors. GLP-1 receptor activation reduces energy intake through central appetitive signaling — suppressing hunger, delaying gastric emptying, and enhancing satiety. These mechanisms are well-characterized from approved GLP-1 receptor agonists such as semaglutide and liraglutide.

Glucagon receptor activation contributes a distinct and additive metabolic dimension. Hepatic glucagon signaling stimulates lipolysis within the liver, promotes fatty acid oxidation, and increases total energy expenditure. Preclinical models have consistently demonstrated that GCGR agonism reduces hepatic fat accumulation — a mechanism with direct relevance to MASH pathology where intrahepatic lipid overload drives steatosis, inflammation, and fibrosis.

Biomarker profiling of survodutide has confirmed dose-dependent engagement of both receptors in clinical settings. Glucagon-related markers (including increased amino acid catabolism and fibroblast growth factor 21 elevation) and GLP-1-related markers (C-peptide increases, glucagon suppression during meals) are both observed, confirming balanced dual agonism rather than predominant activity at one receptor.

The Phase 2 dose-finding trial for obesity enrolled 387 adults (aged 18–74, BMI ≥27 kg/m², without diabetes) across multiple international centers. Participants were randomized to receive once-weekly subcutaneous survodutide at 0.6, 2.4, 3.6, or 4.8 mg, or placebo, over 46 weeks consisting of a 20-week dose-escalation phase followed by 26 weeks of dose maintenance.

Mean body weight reductions were dose-dependent: −6.2% at 0.6 mg, −12.5% at 2.4 mg, −13.2% at 3.6 mg, and −14.9% at 4.8 mg, compared with −2.8% for placebo. Among participants who reached and maintained the 4.8 mg dose, weight loss reached 18.7% — a figure that placed survodutide among the most potent investigational anti-obesity peptides at the time of reporting.

• 83% of participants at 4.8 mg achieved ≥5% body weight loss (vs. 26% placebo)
• 69% achieved ≥10% body weight loss (vs. 11% placebo)
• 55% achieved ≥15% body weight loss (vs. 6% placebo)

The Phase 3 program is evaluating even higher maintenance doses (up to 6.0 mg), which may further increase the magnitude of weight reduction observed in Phase 2. Gastrointestinal adverse events (nausea, diarrhea, vomiting) were the most common treatment-emergent events and were consistent with the known class effects of incretin-based therapies.

The Phase 2 MASH trial, published in The New England Journal of Medicine in June 2024, randomized adults with biopsy-confirmed MASH and fibrosis stages F1 through F3 to receive survodutide (2.4, 4.8, or 6.0 mg weekly) or placebo for 48 weeks, divided into a 24-week rapid-dose-escalation phase and a 24-week maintenance phase.

The primary endpoint — histologic improvement of MASH without worsening of fibrosis — was achieved by 83.0% of survodutide-treated participants at the highest dose, compared with 18.2% on placebo (response difference: 64.8 percentage points, p<0.0001). This represented a landmark result, establishing survodutide as one of the most effective investigational agents for MASH histology improvement reported to date.

For the secondary endpoint of fibrosis improvement by at least one stage, up to 52.3% of survodutide-treated participants achieved this threshold versus 25.8% with placebo (response difference: 26.5 percentage points, p<0.01). The compound also demonstrated substantial reductions in hepatic fat content, with the majority of treated participants achieving ≥30% relative reduction in liver fat as measured by MRI-PDFF.

The SYNCHRONIZE clinical development program encompasses multiple Phase 3 trials designed to evaluate survodutide across the interconnected spectrum of obesity and MASH. The program includes three major studies:

• SYNCHRONIZE-1: Global Phase 3 trial in adults with obesity or overweight without type 2 diabetes. Approximately 600 participants randomized to survodutide (maintenance doses of 3.6 or 6.0 mg) or placebo. Primary endpoints: percent change in body weight and proportion achieving ≥5% weight loss at week 76.
• SYNCHRONIZE-2: Global Phase 3 trial in adults with obesity or overweight with type 2 diabetes. Similar design and endpoints to SYNCHRONIZE-1, evaluating efficacy in the metabolically more complex diabetic population.
• SYNCHRONIZE-CVOT: Long-term cardiovascular outcomes trial in adults with obesity or overweight who have cardiovascular disease, chronic kidney disease, or cardiovascular risk factors. This trial addresses the regulatory and clinical demand for cardiovascular safety and benefit data in the obesity drug class.

All SYNCHRONIZE obesity trials use once-weekly subcutaneous injection with dose escalation to maintenance. Secondary endpoints include the proportion achieving ≥10%, ≥15%, and ≥20% body weight loss at week 76. Topline readouts are anticipated throughout 2026.

In parallel, Boehringer Ingelheim is conducting Phase 3 trials for MASH, building on the Phase 2 NEJM data. The MASH program specifically targets histologic resolution and fibrosis improvement as co-primary endpoints, with liver-related clinical outcomes as long-term secondary measures.

Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) represents one of the most significant unmet needs in hepatology. Characterized by hepatic steatosis, lobular inflammation, and hepatocyte ballooning — often progressing to fibrosis, cirrhosis, and hepatocellular carcinoma — MASH affects an estimated 3–5% of the global adult population, with prevalence rising in parallel with obesity and metabolic syndrome.

Until recently, no pharmacotherapies were approved specifically for MASH. The FDA approval of resmetirom (a thyroid hormone receptor beta agonist) in March 2024 marked the first approved treatment, but the therapeutic landscape remains early-stage with substantial room for agents addressing different pathophysiological mechanisms.

Survodutide's dual-agonist mechanism is particularly relevant to MASH because glucagon receptor activation directly targets hepatic lipid metabolism. While GLP-1 agonists reduce liver fat primarily through weight loss and improved insulin sensitivity, the addition of glucagon receptor agonism provides a liver-directed mechanism: direct stimulation of hepatic fatty acid oxidation, reduced de novo lipogenesis, and enhanced mitochondrial turnover in hepatocytes. This mechanistic rationale explains why survodutide's Phase 2 MASH results exceeded those typically observed with GLP-1 mono-agonists.

Survodutide occupies a distinct position within the emerging landscape of multi-receptor metabolic agonists. Understanding its differentiation requires examining the three major compound classes currently in advanced development:

• Tirzepatide (Eli Lilly): Dual GLP-1/GIP receptor agonist. FDA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). Phase 3 data showed 15–20.9% weight loss at 72 weeks. The GIP component enhances incretin-mediated insulin secretion and may contribute to adipose tissue remodeling, but does not directly target hepatic lipid metabolism.
• Survodutide (Boehringer Ingelheim): Dual GLP-1/glucagon receptor agonist. The glucagon component provides liver-directed fat reduction and increased energy expenditure — mechanisms absent from GLP-1/GIP agonists. Phase 2 showed up to 18.7% weight loss at 46 weeks and 83% MASH histologic improvement.
• Retatrutide (Eli Lilly): Triple GLP-1/GIP/glucagon receptor agonist. Phase 2 demonstrated up to 24.2% weight loss at 48 weeks — the highest reported for any incretin-based therapy. However, adverse event frequency was higher, and Phase 3 data are pending.

A Bayesian network meta-analysis published in 2025 found that dual agonists and retatrutide achieved comparable mean weight loss (approximately −11.0 kg), surpassing GLP-1 receptor mono-agonists (−9.0 kg). Retatrutide showed an advantage for achieving ≥15% weight loss thresholds, but dual agonists demonstrated a more favorable efficacy-to-safety ratio.

For MASH specifically, survodutide's glucagon receptor component provides a mechanistic advantage that neither tirzepatide (GLP-1/GIP) nor current GLP-1 mono-agonists possess. Direct head-to-head trials between these agents have not been conducted, and cross-trial comparisons must be interpreted with caution due to differences in study populations, dose ranges, and endpoints.

The advancement of survodutide into Phase 3 carries several implications for metabolic peptide research. First, positive Phase 3 results would validate the dual GLP-1/glucagon agonist hypothesis in large, controlled populations — confirming that glucagon receptor co-agonism adds clinically meaningful benefit to GLP-1-based therapy for both obesity and MASH.

Second, the SYNCHRONIZE-CVOT trial will provide critical cardiovascular safety and outcomes data. Glucagon receptor agonism carries theoretical cardiovascular considerations (effects on heart rate, blood pressure, and lipid profiles) that require rigorous long-term evaluation. The cardiovascular outcomes data will be essential for regulatory submissions and clinical positioning.

Third, survodutide's development highlights the broader trend toward multi-target peptide therapeutics in metabolic disease. The field is moving from single-receptor agonists (semaglutide, liraglutide) through dual agonists (tirzepatide, survodutide) toward triple agonists (retatrutide), with each generation seeking to engage additional metabolic pathways for enhanced efficacy.

• Phase 3 readouts for both MASH and obesity are expected in 2026, with regulatory submissions potentially following in 2027
• The glucagon receptor component differentiates survodutide from GLP-1/GIP agonists for liver-specific applications
• Cardiovascular outcomes data from SYNCHRONIZE-CVOT will be critical for long-term safety profiling
• Cross-compound comparisons await direct head-to-head trials rather than indirect meta-analytic comparisons

Explore detailed chemical profiles and research guides for compounds discussed in this article:

• Retatrutide: Complete Research Guide → /learn/retatrutide-research-guide-chemical-profile
• Semaglutide: Complete Research Guide → /learn/semaglutide
• Survodutide: Complete Research Guide → /learn/survodutide-research-guide-chemical-profile
• Tirzepatide: Complete Research Guide → /learn/tirzepatide

• Read more: GLP-1 Agonists for Alzheimer's and Parkinson's: 2026 Research Update → https://www.chemverify.com/learn/glp-1-agonists-alzheimers-parkinsons-2026-research-update
• Read more: 23andMe Study: Genetic Variants Predict GLP-1 Drug Efficacy and Side Effects → https://www.chemverify.com/learn/23andme-genetic-variants-glp1-efficacy-side-effects
• Read more: Retatrutide Phase 3 Results: The Triple-Agonist Achieving 28.7% Weight Loss → https://www.chemverify.com/learn/retatrutide-phase-3-results-triple-agonist-weight-loss
• Read more: Tirzepatide vs Semaglutide 2026: SURMOUNT-5 Head-to-Head Results Compared → https://www.chemverify.com/learn/semaglutide-vs-tirzepatide